Answers are grounded in this paper and cite their sources.
The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.
No takes yet. Share an insight, caveat, or question.
Castillo et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: